Peter Blume-Jensen - 31 May 2023 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
President and CEO, Director
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Issuer symbol
ACRV
Transactions as of
31 May 2023
Net transactions value
+$130,387
Form type
4
Filing time
01 Jun 2023, 20:40:34 UTC
Previous filing
16 Nov 2022
Next filing
23 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Options Exercise $130,387 +33,605 +1.4% $3.88 2,403,702 31 May 2023 Direct
holding ACRV Common Stock 320,705 31 May 2023 See footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRV Stock Option (Right to Buy) Options Exercise $0 -33,605 -27% $0.000000 90,855 31 May 2023 Common Stock 33,605 $3.88 Direct F2, F3
holding ACRV Stock Option (Right to Buy) 62,230 31 May 2023 Common Stock 62,230 $3.88 See footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held by Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F2 The shares subject to the option vested or shall vest quarterly on the last day of each quarter for 16 quarters following January 1, 2022, in each case subject to the Reporting Person's continuous service through each such vesting date.
F3 The expiration date for these options was inadvertently reported as April 5, 2032 on the Form 3 filed by the Reporting Person on November 9, 2022, and has been corrected as of this Form 4.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney